Haute MD is the editorial visibility network for distinguished aesthetic, wellness, and specialty physicians, built by Haute Living — a luxury media authority with over 20 years of audience reach across the most financially successful demographics in the United States. Haute MD gives member physicians a premium editorial presence through profiles, professionally written features, treatment coverage, and AI- and search-ready structured content published on HauteLiving.com.

Haute MD is designed for board-certified plastic surgeons, dermatologists, aesthetic physicians, fertility specialists, concierge doctors, and specialty medical professionals in top U.S. markets including New York, Los Angeles, Miami, Chicago, Dallas, Beverly Hills, and Boston.

What does a Haute MD membership include?

Haute MD membership includes a permanent editorial profile on HauteLiving.com, professionally written editorial features and treatment coverage, social amplification across Haute Living's audience, and structured content designed to support discoverability on Google and AI search platforms. Gold and Platinum members also receive dedicated AI Visibility and SEO support. Benefits activate on day one.

How does Haute MD improve AI search visibility?

Haute MD improves AI search visibility by publishing structured physician profiles, editorial features, FAQs, schema markup, and treatment content on HauteLiving.com — a trusted domain indexed by Google News. These assets give AI platforms such as ChatGPT, Google AI Overviews, and Perplexity clear, authoritative context around a physician's specialty, credentials, procedures, and market.

What are the Haute MD membership tiers and pricing?

Haute MD offers three membership tiers: Silver at $500 per year, Gold at $1,500 per year (the most popular tier, which includes AI Visibility and SEO support), and Platinum at $6,000 per year. Founding member pricing locks for life. Applications are reviewed within 48 hours and a full refund is provided if not approved.

Longevity Medicine

What Is MCI (Mild Cognitive Impairment)?

Last reviewed: May 2026 · Haute MD Editorial Team

Mild cognitive impairment (MCI) is measurable cognitive decline beyond what is expected for age and education, but without significant impairment in daily functioning. It is a critical intermediate stage between normal aging and dementia — roughly 10-15% of MCI patients progress to dementia each year — and a key window during which intervention can meaningfully alter trajectory.

How MCI is defined

Diagnostic criteria require: (1) cognitive concern reported by the patient, an informant, or a clinician; (2) objective impairment in one or more cognitive domains on testing, typically 1-2 standard deviations below age-matched norms; (3) preserved independence in functional abilities — patients can still manage finances, medications, and complex tasks, though sometimes with more effort; (4) absence of dementia. MCI is subtyped as amnestic (memory-predominant, more likely to progress to Alzheimer's) or non-amnestic (other domains predominant, more variable etiology). Estimated prevalence is 10-20% in adults over 65. Roughly half of MCI cases are due to underlying Alzheimer's pathology; the remainder reflect vascular disease, Lewy body disease, depression, medication effects, sleep disorders, or reversible causes.

Why MCI matters and what causes progression

MCI is the highest-yield intervention window in cognitive longevity. Annual progression to dementia is ~10-15% per year compared to ~1-2% per year in cognitively normal older adults. However, progression is not inevitable — 20-30% of patients revert to normal cognition on retesting, often when underlying contributors (depression, sleep apnea, polypharmacy, B12 deficiency, hypothyroidism, alcohol use) are addressed. Identifying and aggressively treating reversible contributors is the first step. For MCI due to underlying Alzheimer's pathology, the new amyloid-lowering monoclonal antibodies (lecanemab, donanemab) are FDA-approved for early symptomatic disease and modestly slow progression in selected patients, marking the first disease-modifying therapy available at this stage.

How to evaluate and manage MCI

(1) Formal neuropsychological testing to characterize affected domains and severity; (2) MRI brain to assess for vascular disease, hippocampal volume, and structural abnormalities; (3) Laboratory evaluation — B12, thyroid, HIV, syphilis, celiac, depression screen; (4) Review medications for cognitive impact — anticholinergics, benzodiazepines, opioids, sedating antihistamines; (5) Screen and treat sleep apnea, depression, alcohol use; (6) Aggressive cardiovascular risk reduction — hypertension, diabetes, lipids; (7) Structured exercise (combined aerobic and resistance) has the strongest evidence for cognitive benefit in MCI; (8) Cognitive engagement and social connection; (9) Mediterranean-style diet; (10) Consider amyloid PET or plasma p-tau testing to determine whether MCI is Alzheimer's-related, which guides whether disease-modifying therapy is appropriate. Repeat cognitive testing in 6-12 months to assess trajectory.

Frequently Asked Questions

Will MCI always progress to dementia?

No — annual progression rate is ~10-15%, meaning many patients remain stable for years. About 20-30% revert to normal cognition, particularly when reversible contributors are treated. Etiology matters: amnestic MCI is more likely to progress to Alzheimer's than non-amnestic types.

What's the difference between MCI and normal aging?

Normal aging includes occasional name retrieval problems and slowed processing speed without functional impact. MCI involves measurable test deficits beyond age norms with subjective concern, but preserved independent function. Dementia adds functional impairment.

Are the new Alzheimer's drugs effective for MCI?

Lecanemab and donanemab are approved for early symptomatic Alzheimer's (MCI due to Alzheimer's or mild dementia) and slow cognitive decline by ~25-35% over 18 months in selected patients with confirmed amyloid pathology. They carry significant infusion and imaging requirements and meaningful side-effect risks (ARIA — amyloid-related imaging abnormalities).

What's the most important thing to do if I'm diagnosed with MCI?

Get a thorough workup for reversible causes (sleep apnea, depression, medications, B12, thyroid, alcohol), treat cardiovascular risk factors aggressively, implement structured exercise and Mediterranean diet, and establish a baseline for serial cognitive monitoring.

Get Help Now

Speak with a Haute MD Longevity Medicine physician

Dr. George Kaltner

CEO

Longevity Medicine · Miami Beach, FL

View Profile

Dr. Alexander Golberg

Longevity Medicine · New York, NY

View Profile

Dr. Steven Victor

Regenerative Medicine Specialist

Longevity Medicine · New York, NY

View Profile

View All Longevity Medicine Physicians

Are you a Longevity Medicine physician?

Join Haute MD Network and have your profile featured alongside these answers.

Apply for the Network

Related Guides

Guide · LONGEVITY MEDICINE

What Is Cognitive Testing?

Cognitive testing measures memory, attention, processing speed, and executive function — a key tool for early detection of dementia and cognitive aging.

Read Guide

Guide · LONGEVITY MEDICINE